Biogen BIIB
NASDAQ BIIB
$222.82 -3.06 (-1.35%)
At close: Oct 1, 2026 · 4:00 PM EDT

Biogen (BIIB) Income from Continuing Operations (2009 - 2026)

Updated

Biogen's Income from Continuing Operations was $97.5 million in Q2 2026, down 84.6% from $634.8 million a year earlier and down 69.5% from the prior quarter.

Analysis

Biogen (BIIB) Income from Continuing Operations (2009 - 2026) Analysis & Trends

On a trailing twelve-month basis, Biogen's Income from Continuing Operations was $834.6 million through Jun 30, 2026, down 45.5% year-over-year; for FY2025, it came in at $1.29 billion, down 20.8% from FY2024.

  • Income from Continuing Operations shows a five-year compound annual growth rate of -20.4% (FY2020 to FY2025).
  • In earlier years, Income from Continuing Operations was $1.63 billion in FY2024 (+40.5%), $1.16 billion in FY2023 (-60.7%), $2.96 billion in FY2022 (+74.8%) and $1.69 billion in FY2021 (-58.3%).
  • Quarterly Income from Continuing Operations has moved between -$68.3 million (Q3 2023) and $1.13 billion (Q3 2022) over five years.
  • Compared with a year earlier, Income from Continuing Operations was higher in four of the last six quarters, with an average decline of 9.1%.
  • The best year-over-year quarter for Income from Continuing Operations over five years was Q3 2022 (growth of 258.0%); the worst was Q2 2026 (a decline of 84.6%).
  • Per Business Quant data, BIIB's Income from Continuing Operations in the three quarters before Q2 2026 was $319.5 million (Q1 2026), -$48.9 million (Q4 2025) and $466.5 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 5.53 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 3.62 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -1.34 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 5.28 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 3.09 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 2.38 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -10.50 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -246.00 Mn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 1.10 Bn
10 Biogen 33.37 Bn 20.03 Bn 1.96 Bn 97.50 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 97.50 Mn
Mar 31, 2026 319.50 Mn
Dec 31, 2025 -48.90 Mn
Sep 30, 2025 466.50 Mn
Jun 30, 2025 634.80 Mn
Mar 31, 2025 240.50 Mn
Dec 31, 2024 266.70 Mn
Sep 30, 2024 388.50 Mn
Jun 30, 2024 583.60 Mn
Mar 31, 2024 393.40 Mn
Dec 31, 2023 248.90 Mn
Sep 30, 2023 -68.30 Mn
Jun 30, 2023 593.30 Mn
Mar 31, 2023 387.60 Mn
Dec 31, 2022 549.50 Mn
Sep 30, 2022 1.13 Bn
Jun 30, 2022 1.05 Bn
Mar 31, 2022 221.80 Mn
Dec 31, 2021 -38.20 Mn
Sep 30, 2021 317.00 Mn
API Access

Biogen Income from Continuing Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=BIIB&period=max&api_key=YOUR_API_KEY